Presently the relationship between this amplification and cancer initiation is unknown, however ΔNp63α is a survival factor that opposes a pro-apoptotic gene expression program [15], [16] suggesting a correlation between TP63 amplification and therapeutic resistance. Here, TP63 is linked to cancer.